Evidence map›Paper›PMID 33330814›Full record

ArticleGlobal health & medicine2020

Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial.

Yasuhide Yamada, Kei Muro, Keiichi Takahashi, Hideo Baba, Yoshito Komatsu, Taroh Satoh, Masahiro Goto, Hideyuki Mishima, Masahiko Watanabe, Yuh Sakata and 5 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Gender and sex differences in colorectal cancer screening, diagnosis and treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 14 institutions in 1 country.

Yasuhide YamadaGastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Keiichi TakahashiDepartment of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Hideo BabaDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Yoshito KomatsuCancer Center, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Taroh SatohDepartment of Frontier Science for Cancer and Chemotherapy, Osaka University, Osaka, Japan.
Masahiro GotoCancer Center, Osaka Medical College Hospital, Osaka, Japan.
Hideyuki MishimaAichi Medical University, Nagakute, Aichi, Japan.
Masahiko WatanabeKitasato University Kitasato Institute Hospital, Tokyo, Japan.
Yuh SakataMisawa City Hospital, Misawa, Aomori, Japan.
Satoshi MoritaKyoto University, Kyoto, Japan.
Yasuhiro ShimadaKochi Health Sciences Center, Kochi, Japan.
Naruhito TakenakaTaiho Pharmaceutical Co. Ltd., Tokyo, Japan.
Tadashi HirookaTaiho Pharmaceutical Co. Ltd., Tokyo, Japan.
Kenichi SugiharaTokyo Medical and Dental University, Tokyo, Japan.
Taiho Pharmaceutical (Japan) · JPAichi Cancer Center · JPAichi Medical University · JPHokkaido University Hospital · JPKitasato University · JPKumamoto University · JPKyoto University · JPMisawa City Hospital · JPNational Cancer Center Hospital East · JPOsaka Medical and Pharmaceutical University · JPOsaka University · JPTokyo Medical and Dental University · JPTokyo Metropolitan Komagome Hospital · JPUniversity of Kochi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mechanisms accounting for sex differences in the incidence of adverse events caused by fluoropyrimidine treatments, and histologic differences in efficacy are insufficiently understood. We determined differences between the sexes in terms of the safety of S-1 plus oxaliplatin (SOX)/bevacizumab-versus-l-leucovorin, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX)/bevacizumab, and the impact of histology on their therapeutic effects, in 512 unresectable metastatic colorectal cancer patients from the SOFT phase III study. Nausea (OR: 2.88,

Indexed as

bevacizumabfluorouracilgenderpoorly differentiated adenocarcinomaS-1

Identifiers

PMID33330814
PMCPMC7731258
OpenAlexW3081064000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.